Item no. |
CS-CRP276B |
Manufacturer |
Cell Sciences
|
Amount |
20 ug |
Category |
|
Type |
Proteins |
Specific against |
Human (Homo sapiens) |
Host |
E.coli |
Purity |
>95% by SDS-PAGE and HPLC analyses. |
Sequence |
MQNPASPPEE GSPDPDSTGA LVEEEDPFFK VPVNKLAAAV SNFGYDLYRV RSSMSPTTNV LLSPLSVATA LSALSLGAEQ RTESIIHRAL YYDLISSPDI HGTYKELLDT VTAPQKNLKS ASRIVFEKKL RIKSSFVAPL EKSYGTRPRV LTGNPRLDLQ EINNWVQAQM KGKLARSTKE IPDEISILLL GVAHFKGQWV TKFDSRKTSL EDFYLDEERT VRVPMMSDPK AV |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Similar products |
PEDF, member 1, serine (or cysteine) proteinase inhibitor, EPC-1, PIG35, pigment epithelium-derived factor, proliferation-inducing protein 35, clade F (alpha-2 antiplasmin, pigment epithelium derived factor) |
Available |
|
Biological Activity |
Data Not Available. |
Description |
Pigment Epithelium-derived Factor (PEDF) is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipaselinked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers. |
Endotoxin Level |
Less than 1EU/ug of rHuPEDF as determined by LAL method |
Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in 20 mM PB, pH7.4 + 150 mM NaCl. |
Molecular Weight |
Approximately 44.5 kDa |
Reconstitution |
Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions. |
Storage and Stability |
Stable at 2-8C, but best kept desiccated -20C. Upon reconstitution, stable for up to 1 week at 2-8C. For longer term, store in working aliquots below -20C. Avoid repeated freeze/thaw cycles. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.